Sarepta Therapeutics Up 1.5%

Sarepta Therapeutics is up 1.5% after Aetna (AET) released a new clinical policy bulletin describing the conditions under which it deems Sarepta’s Duchenne muscular dystrophy drug Exondys 51 is medically necessary.

Aetna said it deemed the drug medically necessary when “1) member has a confirmed mutation of the DMD gene amenable to exon 51 skipping; 2) eteplirsen has been initiated in childhood (before 14 years of age); 3) member is able to achieve an average distance of at least 180m while walking independently over six minutes; and 4) medication is prescribed by or in consultation with a physician who specializes in treatment of Duchenne muscular dystrophy.”
For every other indication, it sees the drug as experimental and investigational.

Leave a Comment